JPRN-jRCT1080223158未知Unknown
Special drug use surveillance of Leuplin PRO for Injection Kit 22.5 mg for Prostate cancer
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 333 人开始时间: 2016年4月4日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 发起方
- 入组人数
- 333
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- Male
入选标准
- •Participants with prostate cancer will be included.
排除标准
- •Participants who meet the following criteria will not be included.
- •-Participants with previous history of hypersensitivity to any of the ingredients of the drug or synthetic LH-RH or LH-RH derivatives
研究者
相似试验
招募中
Unknown
Special drug use-results surveillance <Patients with cold agglutinin disease>Cold agglutinin diseaseJPRN-UMIN000049607sanofi K.K.100
已完成
不适用
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion Relapsed or refractory CD30-positive peripheral T cell lymphoma or Pediatric Hodgkin LymphomaPeripheral T cell lymphoma and Pediatric Hodgkin lymphomaJPRN-jRCT1080224999Takeda Pharmaceutical Company Limited95
已完成
Unknown
Special drug use surveillance of Leuprorelin for Injection Kit 22.5 mg in Premenopausal breast cancerPremenopausal breast cancerJPRN-jRCT1080223148Takeda Pharmaceutical Company Limited312
招募中
不适用
Special Drug Use Results Surveillance for the use of Odefsey in pregnant womeHIV/AIDSJPRN-UMIN000034028Janssen Pharmaceutical K.K.3
进行中（未招募）
不适用
Protocol Number; CLCZ696B1401Chronic Heart FailureJPRN-jRCT2031200432Sugimoto Toshiya660